BIOCON.NSBIOCON.NSNSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+10.0%
5Y CAGR+16.5%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+10.0%/yr
vs +17.5%/yr prior
5Y CAGR
+16.5%/yr
Recent deceleration
Acceleration
-7.5pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$35.40B+13.3%
2025$31.24B-4.5%
2024$32.71B+23.1%
2023$26.57B+35.8%
2022$19.56B+18.4%
2021$16.52B+3.6%
2020$15.94B+14.6%
2019$13.92B+68.2%
2018$8.27B-15.7%
2017$9.82B-